Servier acquires potential treatment for Fragile X syndrome, the most common genetic cause of autism spectrum disorder
Servier acquires KER-0193, a potential treatment for Fragile X syndrome, developed by…
Junshi Biosciences Announces the Phase 3 Study of JS005 (IL-17A) for the Treatment of Moderate to Severe Plaque Psoriasis Met Primary Endpoints
SHANGHAI, Sept. 07, 2025 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd…
Encaleret Showed Parathyroid Hormone-Independent Normalization of Blood and Urine Calcium in Phase 2 Proof-of-Concept Study in Post-Surgical Hypoparathyroidism
September 06, 2025 14:30 ET Â | Source: BridgeBio Pharma, Inc. - 80%…
Berlin Heals Holding AG Successfully Raises Over 5Million USD Round for Advancing New Less Invasive Approaches
ZUG, Switzerland, Sept. 1, 2025 /PRNewswire/ -- Berlin Heals Holding AG, a…
Novo Nordisks Wegovy cuts risk of heart attack, stroke or death by 57% compared to tirzepatide in real-world study of people with obesity and cardiovascular diseas
Compared with tirzepatide, Wegovy® (semaglutide 2.4 mg) showed a significant 57% greater…
Angelalign Technology Announces First-Half 2025 Results While Increasing Investments in Legal, Supply Chain and Data Security
SAN CLEMENTE, Calif., Aug. 26, 2025 /PRNewswire/ -- Angelalign Technology Inc. ("Angel"…
Abbott receives regulatory approval for the first denosumab biosimilar in Thailand, expanding access to bone disease treatment
Abbott's denosumab biosimilar is the first approved in Thailand, making advanced therapy for…
Over 2,000 Successful Surgeries for Drug-Resistant Epilepsy
RIYADH, Saudi Arabia, Aug. 25, 2025 (GLOBE NEWSWIRE) -- King Faisal Specialist…
Renaissance Recovery Expands in Florida, Increasing Capacity and Improving Access to Addiction Treatment
In response to the growing need for addiction recovery services, Renaissance Recovery…
Zelluna ASA Reports Second Quarter 2025 Financial Results and Provides General Business Update
Oslo, Norway, 20 August 2025 – Zelluna (OSE: ZLNA), a company pioneering…